On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine kinase (BTK), zanubrutinib (Brukinsa, BeiGene), for chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL).
BTK is a protein critical for the growth and survival of B-cells. BTK inhibitors can kill malignant B-cells but leave healthy T-cells largely unaffected, which distinguishes it from several other treatment methods.
“The approval of zanubritinib is an important advancement for patients diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Each lymphoma patient’s experience is unique, and today’s approval offers patients with CLL/SLL a new treatment option and new opportunity for hope.”